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AbstrAct
Objective The aim of this study was to undertake a 
contemporary review of the impact of exercise-based 
cardiac rehabilitation (CR) targeted at patients with atrial 
fibrillation (AF).
Methods We conducted searches of PubMED, EMBASE 
and the Cochrane Library of Controlled Trials (up until 30 
November 2017) using key terms related to exercise-
based CR and AF. Randomised and non-randomised 
controlled trials were included if they compared the effects 
of an exercise-based CR intervention to a no exercise or 
usual care control group. Meta-analyses of outcomes were 
conducted where appropriate.
Results The nine randomised trials included 959 (483 
exercise-based CR vs 476 controls) patients with various 
types of AF. Compared with control, pooled analysis 
showed no difference in all-cause mortality (risk ratio (RR) 
1.08, 95% CI 0.77 to 1.53, p=0.64) following exercise-
based CR. However, there were improvements in health-
related quality of life (mean SF-36 mental component 
score (MCS): 4.00, 95% CI 0.26 to 7.74; p=0.04 and mean 
SF-36 physical component score: 1.82, 95% CI 0.06 to 
3.59; p=0.04) and exercise capacity (mean peak VO
2: 1.59 
ml/kg/min, 95% CI 0.11 to 3.08; p=0.04; mean 6 min walk 
test: 46.9 m, 95% CI 26.4 to 67.4; p<0.001) with exercise-
based CR. Improvements were also seen in AF symptom 
burden and markers of cardiac function.
Conclusions Exercise capacity, cardiac function, 
symptom burden and health-related quality of life were 
improved with exercise-based CR in the short term (up 
to 6 months) targeted at patients with AF. However, high-
quality multicentre randomised trials are needed to clarify 
the impact of exercise-based CR on key patient and health 
system outcomes (including health-related quality of life, 
mortality, hospitalisation and costs) and how these effects 
may vary across AF subtypes.
IntROduCtIOn
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia and associated with 
increased risks of stroke, heart failure, 
dementia and death.1 AF has a prevalence of 
approximately 2% in adults and increasing 
incidence, mainly due to the ageing popula-
tion.2 3 AF is a highly heterogeneous condi-
tion split in to five diagnostic categories: 
first-diagnosed AF (patient presents with AF 
for the first time), paroxysmal AF (self-lim-
iting and usually the rhythm converts spon-
taneously to sinus (normal) rhythm within 48 
hours), persistent AF (AF episode lasts longer 
than 7 days, or requires cardioversion), 
long-standing persistent AF (duration of AF 
exceeds 1 year) and permanent AF (accepted 
Key questions
What is already known about this subject?
 ► Previous meta-analyses have shown that exer-
cise-based cardiac rehabilitation (CR) targeted 
at patients with atrial fibrillation (AF) can improve 
short-term (up to 6 months) exercise capacity.
 ► However, given the lack of high-quality evidence, 
exercise-based CR is not formally recommended in 
current international guidelines for the management 
of AF.
What does this study add?
 ► This contemporary review confirms that exer-
cise-based CR for AF improves exercise capacity in 
the short term compared with a no exercise control.
 ► This review also shows improvements in health-re-
lated quality of life, cardiac function and symptom 
burden.
How might this impact on clinical practice?
 ► Additional evidence is needed to inform the clinical 
and cost-effectiveness of the provision of exer-
cise-based CR specifically targeted for those with 
AF.
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by the patient (and physician) and no rhythm control 
interventions are used).4 Patients with AF can experi-
ence palpitations, shortness of breath, fatigue, dizziness 
and syncope (fainting), depression, anxiety and reduced 
exercise capacity.3–6
Current AF management mainly focuses on rate and 
rhythm control and reducing stroke risk and its associated 
morbidity and mortality.4 However, although effective in 
managing symptoms and stroke risk, current treatments 
do not focus on patients’ exercise capacity, ability to 
self-manage and mental health.7–9 Poor health-related 
quality of life (HRQoL) therefore remains a common 
and important problem of patients with AF receiving 
conventional medical therapy. HRQoL in patients with 
AF has been shown to be lower than age and sex-matched 
members of the general population and other cardiac 
groups, including coronary heart disease (CHD).9 
Beyond medical management, evidence suggests AF may 
be controlled by improving lifestyle.10 11 One aspect of 
lifestyle therapy that is poorly understood, with respect to 
AF, is regular exercise.12
Mechanisms by which exercise may improve health 
outcomes for patients with AF include atrial remodel-
ling, antiarrhythmic effects via changes in autonomic 
control, reduced blood pressure, reduced bodyweight 
and reduced lipids.13 For example, a study evaluated the 
long-term impact of weight loss on rhythm control of 355 
obese patients (body mass index (BMI) ≥27 kg/m2) with 
AF. Long-term sustained weight loss (≥10%) was associ-
ated with significant reduction of AF burden and main-
tenance of sinus rhythm.14 Exercise has also been shown 
to stimulate improvements in mental health through 
improvements in self-efficacy and reduced inflamma-
tion.15 16
A substantive body of evidence supports the benefits 
of exercise-based cardiac rehabilitation (CR) for CHD 
(post-myocardial and post-revascularisation)17 18 and 
heart failure populations.12 A recent meta-analysis of 33 
randomised trials found that exercise-based CR reduced 
the risk of overall and heart failure-specific hospitalisa-
tion and resulted in improvements in HRQoL compared 
with usual medical care.19 AF is a common comorbidity 
in patients with CHD and heart failure referred to exer-
cise-based CR. However, given the sparse evidence for CR 
specifically targeted for patients with AF, the 2012 Euro-
pean Society of Cardiology and 2011 American College 
of Cardiology/American Heart Association guidelines 
for the management of AF do not formally recommend 
rehabilitation.4 20 21
Since these guidelines were published, a Cochrane 
review in 2017 has found that exercise-based rehabili-
tation programmes targeted at AF patients significantly 
increased their exercise capacity (standardised mean 
difference (SMD): 0.86, 95% CI 0.46 to 1.26) compared 
with no exercise control. However, only a small volume 
of evidence (six randomised trials in 421 patients with 
AF) of moderate to very low-quality and of short-term 
follow-up (up to 6 months) was identified and little or no 
data were available on the impact on HRQoL or clinical 
events, such as mortality and hospitalisation.
Aware that a number of trials have been published 
since this 2017 Cochrane review, we sought to undertake 
a de novo systematic review and meta-analysis to provide 
a contemporary summary of the impact of exercise-based 
CR specifically aimed at patients with AF.
The specific aims of this review were to: (i) investi-
gate if exercise-based CR reduces the risk of mortality 
and hospitalisation of patients with AF; (ii) to identify if 
markers of cardiac function and AF risk are altered with 
exercise-based CR; (iii) and to confirm whether exer-
cise-based CR increases exercise capacity and HRQoL in 
patients with AF.
MetHOds
search strategy
Potential studies were identified by conducting system-
atic searches of PubMed, EMBASE and the Cochrane 
Library of Controlled Trials up until 30 November 
2017. Searches included a mix of MeSH and free text 
terms related to the key concepts of exercise-based 
CR, atrial fibrillation, arrhythmia, heart rate and 
heart rate variability. In addition, systematic reviews, 
meta-analyses and reference lists of papers were hand 
searched for additional studies. One reviewer (NAS) 
conducted the search and full articles were assessed 
for eligibility by two reviewers (NK and NAS) using 
the inclusion criteria. A sample search strategy is 
presented in online supplementary files. Authors were 
contacted and asked to provide clarification of study 
information if needed.
study type and participants
Randomised controlled trials (RCTs) and non-RCTs 
of exercise training in adult patients with AF were 
included. Abstracts and non-English language studies 
were excluded.
Intervention
Exercise-based CR was defined to allow for inclusion of 
a broad range of physical activities, including aerobic, 
resistance exercise training, combined training (aerobic 
and resistance), yoga, pilates, Tai Chi and hydrotherapy. 
Additionally, the physical therapies of Functional Elec-
trical Stimulation and Inspiratory Muscle Training were 
included in the definition of exercise-based CR for the 
purpose of this review. To be included in the review, 
studies had to compare an exercise-based CR interven-
tion to no exercise or usual care, or ‘other exercise’ 
control groups and the duration of the exercise-based 
CR had to be a minimum of 4 weeks. We also included 
trials that included exercise-based CR with other inter-
ventions including education and psychological support 
as many contemporary rehabilitation programmes use 
all three components.
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Figure 1 PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
Outcomes
Primary
i. All-cause mortality and all-cause hospitalisation.
ii. HRQoL: any validated HRQoL questionnaire was 
included.
iii. Exercise capacity, for example, peak VO2 or 6 min 
walk distance.
Secondary
i. Measures of cardiac function, for example, resting 
heart rate.
ii. Other clinical risk factors associated with AF, for ex-
ample, AF burden or AF symptoms.
data extraction
Two reviewers (NAS, NK) extracted the following 
information for each study: (1) author, year of publi-
cation and study design; (2) AF patient demographic 
and clinical characteristics (eg, age or type of AF); (3) 
exercise intervention characteristics (eg, duration, 
modality, frequency, intensity); (4) number of patient 
events (binary outcomes), or mean and SD (or SE, p 
value or 95% CIs) (continuous outcomes); (5) char-
acteristics of assessment methodology for AF and (6) 
reporting of adverse events and intervention compli-
ance.
data synthesis
Statistical analyses were performed using Revman V.5.3 
(The Nordic Cochrane Centre, Copenhagen, Denmark). 
For meta-analysis of binary data, risk ratios (RRs) were 
calculated. Individual meta-analyses were completed for 
continuous data by using the mean baseline follow-up 
change and SD. Where the mean change and SD were 
not reported, this was calculated by subtracting the 
follow-up mean from the baseline mean, and Revman 
V.5.3 enabled calculations of SD using number of partic-
ipants in each group, within-group or between-group p 
values or 95% CI. In cases where exact p values are not 
provided, we used default values, for example, p<0.05 
becomes p=0.049, p<0.01 becomes p=0.0099 and p=not 
significant becomes p=0.051. Where data were reported 
as median, the median was assumed to equal the mean. 
Data not provided in main text or tables were extracted 
from figures. For continuous data, MD was used where 
outcome measures were homogenous. Where outcome 
measures were measured by different methods, SMD 
was used. Statistical heterogeneity was quantified using 
the I2 test. Values ranged from 0% (homogeneity) to 
100% (high heterogeneity).22 A fixed effects meta-anal-
ysis model was used when there was evidence of no 
statistical heterogeneity (ie, I2 statistic ≤50%) and a 
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Table 1 Included studies
Study Inclusion criteria Intervention: control Exercise/control Outcomes
Hegbom 25 Patients with chronic AF,<75 
years.
Exercise
8 weeks, three sessions/week. Supervised, 
1.25 hours, aerobic exercise: 5 min warm-up, 
3×15 min periods of aerobics @ 70%–90% 
HRmax interrupted by strengthening exercise 
(back, thighs and stomach), followed by a 
5 min cool-down and 15 min of stretching. 
Sessions completed @ one of two 
rehabilitation Centres.
Control
Usual care.
15/15 randomised
13/15 analysed
Heart rate variability
Maximal heart rate
Resting heart rate
Cumulated workload (W)
Exercise time max. (min)
QoL (SF-36)
Luo 2 Heart failure patients with 
LVEF <35%. Sub-analysis 
of those with AF from HF 
ACTION trial.
Exercise
12 weeks, three sessions/week. Supervised 
aerobic exercise (walking, treadmill, or cycle 
ergometer), followed by transition to a home-
based exercise programme for an additional 
2 years.
Control
Usual care.
193/189 randomised 
and analysed
6MWD
Peak VO2
QoL (KCCQ)
All-cause mortality/ hospitalisation
Cardiovascular mortality/HF 
hospitalisation
Malmo 26 Patients with non-
permanent AF (paroxysmal 
or persistent)
Exercise
12 weeks, three sessions/week. Aerobic 
(walking/running), 10 min warm-up @ 60%–
70% HRpeak, then 4×4 min intervals @ 85%–
95% of HRpeak with 3 min of active recovery @ 
60%–70% HRpeak between intervals.
Control
Usual care.
26/25 randomised and 
analysed
Time in AF
AF symptoms and severity
Blood pressure
Resting heart rate
Peak heart rate
Cardiac volumes (ejection fraction)
QoL (SF-36)
Peak VO2
lipid status (TC, HDL, LDL, TG) 
hsCRP
BMI, weight
activity
Osbak 27 Adults with permanent AF. Exercise
12 weeks, three sessions/week, @ 70% 
maximal exercise capacity (Borg scale scores 
14–16). Total exercise duration was 60 min 3, 
minimum 30 min @ 70% maximal exercise 
capacity.
Control
Usual care.
25/24 randomised
24/23 analysed
CO (maximal and resting)
Maximal heart rate
Resting heart rate
Blood pressure
Heart rate reserve
6MWD
Maximal power (W)
QoL (MLHF-Q and SF-36)
ANP, NT-pro-BNP
Adverse events
Pippa 28 Patients diagnosed with 
AF at least 3 months prior, 
and taking anticoagulant 
treatment for at least 2 
months.
Exercise
16 weeks, two sessions/week. 90 min 
sessions of qi gong training. Qi gong refers to 
a set of static exercises.
Control
Usual Care.
22/21 randomised and 
analysed
6MWD
BMI
Lipids (TC, HDL)
Homocysteine
Ejection fraction
Adverse events
Risom 29 Consecutive patients 
planned for treatment with 
radiofrequency catheter 
ablation,≥18 years. 
Paroxysmal or persistent AF.
Exercise
12 weeks, three sessions/week, graduated 
cardiovascular training based on Borg 
15-point scale and strength exercises.
Control
Usual care.
105/105 randomised* Peak VO2
Maximal power (W)
STS
Max. blood pressure
QoL (SF-36, HADS)
EHRA score
Mortality, adverse events
Continued
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Study Inclusion criteria Intervention: control Exercise/control Outcomes
Skielboe 10 Patients with paroxysmal/ 
persistent AF.
Exercise
12 weeks, two sessions/week, 60 min/
session, high Intensity – (80% of maximal 
RPE).
Comparator
12 weeks, two sessions/week, 60 min/
session, low Intensity (50% of maximal RPE).
38/38 randomised†
26/29 analysed†
Burden of AF (time spent in AF)
Peak VO2
Hospital admissions
Adverse events
Wahlstrom 31 Patients with paroxysmal 
AF, necessitating 
pharmacological treatment.
Exercise
12 weeks, one session a week, 60 min group 
session of yoga (Mediyoga) and encouraged to 
practice at home.
Control
Usual care.
40/40 randomised
33/36 analysed
QoL (SF-36, EuorQoL-5D)
Resting heart rate
Blood pressure
Zeren 30 Patients with permanent AF, 
LVEF >40%.
Exercise
12 weeks, 2×15 min sessions, 7 days/week. 
Inspiratory muscle training a@ 30% MIP.
Control
Usual care.
19/19 randomised
17/16 analysed
Pulmonary function
Respiratory muscle strength
Adverse events
*Different numbers for analysis at different time points for different outcomes.
†Performed ITT analysis and per protocol analysis.
ACR, Albumin: Creatinine ratio; AF, Atrial Fibrillation; ANP, Atrial Natriuretic Peptide; BMI, Body mass index; ERHA, European Heart Rhythm 
Score; HADS, Hospital anxiety and depression score; HD, High density lipoprotein; HF, Heart failure; KCCQ, Kansas City Cardiomyopathy 
Questionnaire; LDL, Low density lipoprotein; MLHF-Q, Minnesota living with heart failure questionnaire; 6MWD, 6 minute walk distance; NT-
Pro-BNP, N-terminal Pro-Brain Natriuretic Peptide; QoL, Quality of life; RPE, Rate of Perceived Exertion; SF-36, Short form-36; STS, Sit-to 
stand test; TC, Total cholesterol; TG, Triglycerides; eGFR, estimated Glomerular Filtration Rate; hsCRP, high-sensitive C-reactive protein.
Table 1 Continued
random effects inverse variance model was used when 
the I2 statistic >50%. We judged statistical significance 
based on 5% level of significance and reported pooled 
mean results with 95% CIs. Where a study included 
multiple intervention groups and a control group, 
each intervention group was considered separately and 
the sample size of the control group was divided by 
the number of intervention groups to eliminate over 
inflation of the sample size. If data were reported for 
multiple time points during the intervention, only the 
data at the end of the intervention were extracted as 
long as data were available for both the intervention 
and control group. Where two publications referred 
to the same study population, the publication with the 
highest number of participants was used. Visual inspec-
tion of funnel plots23 was used to assess risk of publica-
tion bias.
study quality
Study quality was assessed using the TESTEX; the Tool 
for assessment of study quality and reporting, designed 
specifically for use in exercise training studies.24 
This is a 15-point scale that assesses study quality 
(maximum 5 points) and reporting (maximum 10 
points). Two reviewers (RST and NAS) independently 
conducted quality assessment. A study quality score 
<10 was considered low quality. If relevant subanalyses 
were conducted by removing low-quality studies from 
pooled analyses.
Results
Our initial search identified 1701 titles, and hand 
searching a further 7 potential studies for inclu-
sion. Fifty-two duplicate studies were removed, and a 
further 1617 papers excluded as they were not RCTs 
or non-RCTs. Thirty studies were excluded at full text 
screening as they were not studies of exercise-based 
CR in adults with AF. Also, 13 were acute (single exer-
cise session) studies, 16 were not AF studies and 1 was 
a paediatric study. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses flow diagram 
(figure 1) describes the selection process. Nine studies 
(nine publications) were included in this analysis2 10 25–31 
(see table 1).
trial and patient characteristics
Eight RCTs compared exercise-based CR with control 
participants, while one RCT compared high-intensity 
exercise training versus exercise at lower intensity.10 
The total number of participants in the nine included 
studies yielded 959 participants, 483 allocated to exercise 
training and 476 to control. One study, in addition to the 
exercise component, also included a psycho-educational 
part of the intervention.29
study quality and risk of bias
Median TESTEX score was 12 out of 15. Monitoring of 
physical activity in the control group (3/9 studies) and 
assessment of energy expenditure during training (4/9 
studies) were the only two items not performed by at 
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least 50% of studies; see table 2. Two studies produced a 
TESTEX score <10.
Primary outcomes
Mortality and hospitalisation
Evidence from pooled analysis of eight studies2 25–31 
showed 52 deaths in 445 (11.7%) exercising participants 
and 47 deaths in 438 (10.7%) control participants. There 
was no significant difference in pooled RR between exer-
cise-based CR and control groups (RR 1.08, 95% CI 0.77 
to 1.53, p=0.64, I2=0%) (figure 2). There were 156 occur-
rences of either all-cause mortality or hospitalisation 
reported in 386 (40.4%) intervention participants and 
147 occurrences in 379 (38.7%) control participants (RR 
1.04, 95 CI% 0.93 to 1.16, p=0.51, I2=0%) (figure 3).
HRQoL
Five studies reported on HRQoL using SF-36; however, 
Hegbom et al25 only reported combined intervention 
and control data and therefore could not be pooled. 
Three studies reported SF-36 MCS26 29 31; pooled anal-
yses showed a significant improvement in MCS in exer-
cise-based CR versus control participants (MD 4.00, 95% 
CI 0.26 to 7.74; p=0.04, I2=62%) (figure 4). Three studies 
reported SF-36 physical component scores (PCS)26 29 31; 
pooled analyses showed a significant improvement in 
PCS in exercise-based CR versus control participants (MD 
1.82, 95% CI 0.06 to 3.59; p=0.04, I2=26 %) (figure 5). 
Analyses also demonstrated a significant improvement in 
the SF-36 subscale of vitality in exercise-based CR versus 
control (MD 8.33, 95% CI 2.15 to 14.52 p=0.008, I2=54%) 
(see online supplementary file), and SF-36 general health 
(MD 7.54, 95% CI 4.63 to 10.44, p<0.001, I2=50%) (see 
online supplementary file). One study2 measured self-re-
ported HRQoL using the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) with only minimal improvements 
observed from exercise-based CR.
Exercise capacity
Three studies reported peak VO2 (2, 26, 29) and pooled 
analysis showed a significant improvement in interven-
tion vs control participants for peak VO2 (MD 1.59 ml/
kg/min, 95% CI 0.11 to 3.08; p=0.04 I2=82%) (figure 6). 
Five studies reported 6 min walk distance and pooled 
analysis showed a significant improvement in interven-
tion versus control participants (MD 46.93 m, 95% CI 
26.44 to 67.42; p<0.001, I2=66%) (figure 7).
secondary outcomes
Cardiac function
Four studies reported resting heart rate25–27 31; however, 
Hegbom et al25 only provided combined intervention and 
control data. Pooled analysis of available data from three 
studies26 27 31 showed resting heart rate to be reduced in 
exercising versus control participants (MD −4.61 beats/
min, 95% CI −7.42 to −1.80, p=0.001); I2=45% (see online 
supplementary file). Maximal heart rate was reduced in 
exercising versus control participants; (MD −2.95 beats/
min, 95% CI −5.31 to −0.59, p=0.01; I2=50%) (see online 
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Figure 2 All-cause mortality.
Figure 3 All-cause mortality or hospitalisation.
supplementary file). Left ventricular ejection fraction 
was assessed by measuring the volume of blood ejected 
from the left ventricular chamber using MRI26 and two-di-
mensional echocardiography.28 Left ventricular ejection 
fraction was significantly increased by exercise-based CR 
versus control (MD 4.31%, 95% CI 2.12 to 6.51, p<0.001; 
I2=0%) (see online supplementary file). One study 
reported left atrial volume to be unchanged after exer-
cise-based CR versus control (MD 0.0 cm3, 95% CI-6.49 
to 6.49, p=1.00).
AF burden and symptoms
Two studies reported time spent in AF.10 26 Malmo et 
al26 observed a decrease in mean time spent in AF from 
8.1% to 4.8% in the exercise-based CR group, which 
was significantly different from controls (MD 7.6%, 
95% CI 2.0 to 13.0, p=0.001). Three studies reported 
on AF symptoms25 26 29; however, Hegbom only reported 
combined intervention and control data. Malmo et 
al26 reported changes in AF symptoms, assessed by 
the AF Symptoms and Severity Checklist, with signifi-
cant reductions in symptom frequency and severity, 
compared with controls (p<0.01). Risom et al29 reported 
no significant difference in European Heart Rate Asso-
ciation (EHRA) scores between exercise-based CR and 
control groups.
Clinical risk factors
Pooled data from three studies26–28 indicated a decrease in 
systolic and diastolic BP; however, this was not statistically 
significant (see online supplementary file). Two studies 
reported BMI changes. A statistically significant change 
in BMI compared with controls was observed by Malmo et 
al26 , while no change was observed by Pippa et al.28 Simi-
larly, in patients with permanent AF, Osbak et al27 failed 
to observe any changes between groups for lean body 
mass or fat percentage. Malmo et al observed significant 
decreases in total cholesterol, low-density lipoprotein and 
triglycerides compared with controls. In contrast, Pippa et 
al reported no change in total cholesterol.
Analyses of high-intensity versus lower-intensity exercise training
Skielboe et al10 reported no significant differences 
between groups exercising at higher versus lower intensi-
ties for any of the outcome measures.
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Figure 4 Change in SF-36 mental component score.
Figure 5 Change in SF-36 physical component score.
Publication bias
Examination of funnel plots showed no evidence of 
publication bias.
dIsCussIOn
This updated systematic review and meta-analysis 
provides a contemporary summary of the impact of 
exercise-based CR aimed at patients with AF.12 We 
included data from nine randomised trials in a total 
of 959 patients with various types of AF. Our study 
shows improvements in exercise capacity, HRQoL and 
various measures of cardiac function, and AF symptom 
burden in the short term (up to 6 months) following 
exercise-based CR compared with no exercise control. 
However, there was insufficient evidence to determine 
if the benefits of exercise-based CR vary across types of 
AF, to assess the impact of CR on the risk of mortality 
or hospitalisation or to determine the optimal exercise 
training intensity to elicit beneficial health outcomes.
Comparison with previous studies
Compared with the 2017 Cochrane review, our study 
included an additional three randomised trials and an 
additional 538 patients with AF. Our pooled analysis 
failed to show a reduction in mortality and hospitali-
sation due to insufficient evidence, consistent with the 
previous Cochrane review.12 However, our findings of 
the positive impact of exercise-based CR on exercise 
capacity are consistent with this previous Cochrane 
review. Our analysis showed that mean peak VO2 was 
improved by about 1.6 ml/kg/min after exercise-based 
CR which corresponds to ~0.5 METs in people with 
AF. These findings correspond with a meta-analysis of 
41 trials of people with CHD and heart failure which 
found a pooled MD of 3.3 ml/kg/min for VO2 in favour 
of CR32 (corresponding to ~1.0 METs). It would take a 
typically deconditioned cardiac patient with AF with a 
peak VO2 value of ~13 ml/kg
/min to a value >14 ml/kg/
min.33 34 This is clinically meaningful as it would reduce 
the mortality and morbidity risk of such a patient35 
and represents an absolute change of 4%–5% which 
would be noticeable in terms of associated symptoms, 
for example, dyspnoea. The observed mean improve-
ment in 6 min walk distance of 47 m is also above the 
minimally clinically important difference of 41.8 m 
previously reported.36 Importantly this updated review 
provides additional evidence of the potential benefit on 
HRQoL.
Our analyses showed that exercise-based CR can 
impact on the various subscales of HRQoL. Both the 
MCS and PCS of the SF-36 demonstrated significant 
improvements.12 It is has been proposed that compared 
with disease-specific measures generic HRQoL 
measures (such as the SF-36) may lack the sensitivity 
to AF-specific symptoms and specific barriers unique to 
AF.37 However, given that we were able to see improve-
ments using a generic HRQoL instrument other factors 
may also be relevant here. For example, non-specific 
factors such as depression, anxiety and fear of social 
isolation associated with the risk of a stroke are likely to 
a major concern for people with AF.38
Resting heart rate was reduced in exercising partic-
ipants possibly reflecting better rate control which is 
important in AF.39 40 Previous work has shown a j-shaped 
relationship between heart rate and mortality in people 
with AF.39 Maximal heart rate was also reduced by 
about 1.7 beats per minute less than resting heart rate 
reduction. However, heart rate reserve (the difference 
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Figure 6 Change in VO2 peak.
Figure 7 Six-minute walk test.
between resting and maximum heart rate) was not 
reported in any of the included studies. Impaired heart 
rate reserve in patients with permanent AF treated 
according to a strict rate-control strategy is associated 
with an increased risk of hospitalisation for patients 
with heart failure.41 It is important to note that there 
is no defined clinical end point for heart rate control. 
For example, the RACE-II trial compared lenient 
rate control (target resting heart rate <110 bpm) to 
strict rate control (target resting heart rate <80 bpm) 
and found no differences in mortality, hospitalisa-
tion, stroke, systemic embolism, major bleeding and 
arrhythmic events (HR 0.84; 90% CI 0.58 to 1.21).42
Our analysis showed left ventricular ejection fraction 
was significantly increased by exercise-based CR versus 
control participants. This is especially important in 
people with AF who derive great benefit from improved 
systolic function.43 Limited data from only one study26 in 
this analysis reported left atrial volume to be unchanged 
after exercise-based CR versus control. Larger left atrial 
size is a strong predictor of AF initiation and propa-
gation, and therefore, any reduction in this parameter 
is likely to increase the likelihood of a rhythm control 
strategy.44 Data on ejection fraction were collected 
using MRI26 and two-dimensional echocardiography.28 
Both of these approaches use Simpson’s rule to calcu-
late ventricular volume, which brings some consistency. 
However neither study mentioned, number of beats nor 
HR at time of recording which given the heterogeneous 
nature of AF in any given patient could have been a 
limitation. Finally, it is important to recognise that 
diastolic function is being recognised as an important 
risk factor for AF.45 Left ventricular diastolic function 
has been shown to be able to predict the occurrence 
of AF even when other cardiovascular risk factors are 
controlled for.46 However, there were insufficient data 
in the included studies to allow meaningful analyses.
strengths and limitations
We believe this to be the most comprehensive systematic 
review of exercise-based CR for AF to date and found 
no evidence of publication bias. However, we recog-
nise this study had a number of limitations. First was 
the small number of eligible studies and considerable 
variability in terms of their interventions, participants 
and outcomes. As a result, data pooling was limited to 
small patient numbers and to small number of common 
outcomes. The exercise-based CR programmes varied 
greatly between studies with respect to exercise inten-
sity, duration, frequency and modality. Second, AF 
burden is difficult to measure due to its heterogeneous 
nature, and the fact that frequency of symptom severity 
varies between different AF subtypes. Finally, given 
the lack of studies and lack of availability of individual 
patient data no subgroup analyses in relation to the 
clinical sub-types of AF (ie, first-diagnosed AF, parox-
ysmal AF, persistent AF, long-standing persistent AF and 
permanent AF) could be carried out.
Implications for clinical practice and future research
Exercise-based CR represents a promising interven-
tion for people with AF. However, due to insufficient 
evidence, we believe it is premature to recommend exer-
cise-based CR targeted at patients with AF. Future large-
scale trials with well-developed and delivered inter-
ventions should be conducted to understand if exer-
cise-based CR can elicit long-term effects on HRQoL 
and other important clinical outcomes in people with 
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AF. Such trials should also be adequately powered to 
investigate potential variations in the impact of exer-
cise-based CR across the various clinical subtypes of AF.
COnClusIOn
Exercise capacity, measures of cardiac function, AF 
symptom burden and HRQoL were seen to improve in 
the short term (up to 6 months) with exercise-based CR 
in people with AF compared with no exercise control. 
There appeared to be no differences in outcomes 
between exercise at high and lower intensity. Further 
high-quality randomised trials which target the specific 
subtypes of AF are needed to definitively assess the 
impact of exercise-based CR on key patient and health-
care system outcomes, including HRQoL, clinical 
events and costs.
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